Syros Pharmaceuticals (SYRS) Earns Daily Coverage Optimism Score of 0.12
News headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.5534068416498 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down 2.20% during midday trading on Thursday, reaching $19.55. 56,669 shares of the company traded hands. The company’s 50 day moving average is $20.27 and its 200-day moving average is $16.09. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $24.38. The stock’s market capitalization is $513.38 million.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. Equities research analysts forecast that Syros Pharmaceuticals will post ($2.09) earnings per share for the current fiscal year.
SYRS has been the topic of a number of research analyst reports. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Cann reissued a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Cowen and Company reissued a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Finally, JMP Securities downgraded shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $20.81.
In other Syros Pharmaceuticals news, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at $273,125. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $23.59, for a total transaction of $58,975.00. Following the transaction, the insider now directly owns 2,500 shares in the company, valued at $58,975. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,564 shares of company stock worth $476,803.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.